Clinical Trial Update: Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder [Phase 2]

View source ↗

Summary

Clinical trial update indicating a Phase 2 study of eculizumab for acute attacks in neuromyelitis optica spectrum disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Status: RECRUITING